12407 N. MOPAC EXPY., AUSTIN, TX
Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics Enters $2.3M Private Placement with Institutional Investors
Director Resignation - Manuel C. Alves Aivado Steps Down from Board
Rein Therapeutics Enters $2.5M Securities Purchase Agreement with Funicular
Rein Therapeutics Terminates Pre-Paid Advance and Standby Equity Agreements
Other Events
Rein Therapeutics Enters $6 Million Pre-Paid Advance Agreement with Yorkville
Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Q1
Amended Annual Report
Q3
Q2
FY 2024
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
S-1
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Free Writing Prospectus